Xin Lang Cai Jing·2026-02-27 11:45Group 1 - The A-share medical sector showed positive performance on February 27, with the largest medical ETF (512170) rising by 1.14% and successfully recovering the annual line, with a transaction volume of 384 million CNY [1][9] - The ETF experienced continuous premium trading, indicating a positive buying sentiment, with over 190 million CNY net subscriptions in the previous three days [1][9] - The leading stock, Huatai Medical, surged by 8.24%, with its performance report indicating over 20% year-on-year growth in revenue and net profit for 2025 [1][11] Group 2 - The Hong Kong medical sector rebounded after several days of decline, with the Hong Kong medical ETF (159137) recovering from a historical low, ending a six-day losing streak [3][11] - CXO companies, particularly those under WuXi AppTec, showed strong performance, with shares rising by 8.23% for WuXi AppTec, 5% for WuXi Biologics, and 3.21% for WuXi AppTec [3][11] - Citic Securities remains optimistic about the growth potential and space for the CXO sector due to increasing overseas orders and a gradual recovery in domestic demand [4][12] Group 3 - In the medical device industry, Citic Securities believes that policy impacts will eventually clear, and companies will gradually recover after strategic adjustments, suggesting an allocation increase in 2026 [6][14] - Investment opportunities are expected to arise from performance recovery, international expansion, brain-computer interfaces, and AI medical applications [6][14] - The medical ETF fund size reached 27.7 billion CNY, making it the largest in the medical sector, covering various themes including brain-computer interfaces and innovative medical devices [7][14]